PCT/EP2004/004280

8.

 $12-15 \text{ g/m}^2$.

35

7

CLAIMS

Sachet for a pharmaceutical composition, 1. comprising the layers: 5 i) paper; bonding layer; iii) barrier layer; and sealing layer. iv) Sachet according to claim 1, wherein said 10 2. barrier layer is an aluminum foil, said bonding layer is preferably of polyethylene, and said sealing layer is preferably a low density polyethylene. 15 Sachet according to claim 1 or 2, wherein said 3. paper i) has a weight per unit area of 10-100 q/m^2 . Sachet according to claim 3, wherein said paper 4. 20 i) has a weight per unit area of $30-70 \text{ g/m}^2$. Sachet according to claim 4, wherein said paper 5. i) has a weight per unit area of $40-60 \text{ g/m}^2$. 25 6. Sachet according to any of the preceding claims, wherein said bonding layer ii) has a weight per unit area of $6-20 \text{ g/m}^2$. Sachet according to claim 6, wherein said 7. 30 bonding layer ii) has a weight per unit area of 9-18 g/m^2 .

Sachet according to claim 7, wherein said

bonding layer ii) has a weight per unit area of

WO 2004/093883 PCT/EP2004/004280

8

- 9. Sachet according to any of the preceding claims, wherein said sealing layer iv) has a thickness of 15-50 μm .
- 5 10. Sachet according to any of the preceding claims, wherein said sealing layer iv) has a weight per unit area of 10-100 g/m², more preferred 15-75 g/m², preferably 20-50 g/m², more preferably 30-40 g/m², most preferred 35 g/m².
 - 11. Sachet according to any of the preceding claims, wherein said barrier layer iii) has a thickness of 6-30 μm, more preferred 7-25 μm, preferably 9-25 μm, more preferred 8-20 μm, preferably 9-15 μm, more preferred 12 μm.
- 12. Sachet according to any of the preceding claims, containing a pharmaceutical formulation.

15

25

- 13. Sachet according to claim 12, wherein said pharmaceutical formulation comprises mesalazine or a pharmaceutically acceptable salt thereof.
- 14. Sachet according to claim 12 or 13, said sachet containing an oral pharmaceutical formulation in the form of a granulate comprising more than 55% by weight of mesalazine or a pharmaceutically acceptable salt thereof.
 - 15. Use of sachet according to any of the preceding claims for a pharmaceutical composition.
- 35 16. Use of a sachet according to any of the claims 1 - 14 for medical purposes.